A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens

References

• Leoni V, Biondi A. Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia. Haematologica. 2015;100:295–299. doi:10.3324/haematol.2015.124016
   PubMedGoogle Scholar
• Jabbour E, Pui CH, Kantarjian H. Progress and innovations in the management of adult acute lymphoblastic leukemia. JAMA Oncol. 2018;4:1413–1420. doi:10.1001/jamaoncol.2018.1915
   PubMed Web of Science ®Google Scholar
• Bassan R, Rossi G, Pogliani EM, et al. Underuse of anthracyclines in women with HER2-positive advanced breast cancer. J Clin Oncol. 2010;28:1120–11120. doi:10.1200/jco.2010.28.15_suppl.1120
   Web of Science ®Google Scholar
• Chalandon Y, Thomas X, Hayette S, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015;125:3711–3719. doi:10.1182/blood-2015-02-627935
   PubMed Web of Science ®Google Scholar
• Jones D, Thomas D, Yin CC, et al. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer. 2008;113:––994. doi:10.1002/cncr.23912
   Web of Science ®Google Scholar
• Xu N, Li YL, Li X, et al. Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. J Hematol Oncol. 2016;9:40. doi:10.1186/s13045-016-0270-5
   PubMed Web of Science ®Google Scholar
• Brown PA, Shah B, Advani A, et al. Acute lymphoblastic leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19:1079–1109. doi:10.6004/jnccn.2021.0042
   PubMed Web of Science ®Google Scholar
• Wei AH, Ribera JM, Larson RA, et al. Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia. Leukemia. 2021;35:2220–2231. doi:10.1038/s41375-020-01089-x
   PubMed Web of Science ®Google Scholar
• Fujisawa S, Mizuta S, Akiyama H, et al. Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Am J Hematol. 2017;92:367–374. doi:10.1002/ajh.24653
   PubMed Web of Science ®Google Scholar
• Biondi A, Gandemer V, De Lorenzo P, et al. Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial. Lancet Haematol. 2018;5:e641–e652. doi:10.1016/S2352-3026(18)30173-X.
   PubMed Web of Science ®Google Scholar
• Lou Y, Ma Y, Li C, et al. Efficacy and prognostic factors of imatinib plus CALLG2008 protocol in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Front Med. 2017;11:229–238. doi:10.1007/s11684-017-0506-y
   PubMed Web of Science ®Google Scholar
• Daver N, Thomas D, Ravandi F, et al. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica. 2015;100:––661. doi:10.3324/haematol.2014.115055
   Web of Science ®Google Scholar
• Lim SN, Joo YD, Lee KH, et al. Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol. 2015;90:1013–1020. doi:10.1002/ajh.24137
   PubMed Web of Science ®Google Scholar
• Shen S, Chen X, Cai J, et al. Effect of dasatinib vs imatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial. JAMA Oncol. 2020;6:358–366. doi:10.1001/jamaoncol.2019.5868
   PubMed Web of Science ®Google Scholar
• Sugiura I, Doki N, Hata T, et al. Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Adv. 2022;6:624–636. doi:10.1182/bloodadvances.2021004607
   PubMed Web of Science ®Google Scholar
• Slayton WB, Schultz KR, Kairalla JA, et al. Dasatinib plus intensive chemotherapy in children, adolescents, and young adults With Philadelphia chromosome-positive acute lymphoblastic leukemia. Results of Children's Oncology Group Trial AALL0622. J Clin Oncol. 2018;36:2306–2314.
   PubMed Web of Science ®Google Scholar
• Wieduwilt MJ, Yin J, Wetzler M, et al. Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL. Blood Adv. 2021;5:4691–4700. doi:10.1182/bloodadvances.2021004813
   PubMed Web of Science ®Google Scholar
• Rousselot P, Coude MM, Gokbuget N, et al. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood. 2016;128:774–782.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Othus M, O'Brien SM, et al. US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL. Blood Adv. 2016;1:250–259. doi:10.1182/bloodadvances.2016001495
   PubMed Web of Science ®Google Scholar
• Liu B, Wang Y, Zhou C, et al. Nilotinib combined with multi-agent chemotherapy in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center prospective study with long-term follow-up. Ann Hematol 2019;98:633–645. doi:10.1007/s00277-019-03594-1
   PubMed Web of Science ®Google Scholar
• Kim DY, Joo YD, Lim SN, et al. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Blood. 2015;126:746–756.
   PubMed Web of Science ®Google Scholar
• Ribera J-M, García-Calduch O, Ribera J, et al. Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Advances. 2022;6:5395–5402. doi:10.1182/bloodadvances.2022007764
   PubMed Web of Science ®Google Scholar
• Jabbour E, Short NJ, Ravandi F, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol. 2018;5:e618–e627. doi:10.1016/S2352-3026(18)30176-5
   PubMed Web of Science ®Google Scholar
• Sasaki K, Jabbour EJ, Ravandi F, et al. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2016;122:3650–3656. doi:10.1002/cncr.30231
   PubMed Web of Science ®Google Scholar
• Othman T, Moskoff BN, Ho G, et al. Clinical experience with frontline hyper-CVAD-based regimens, including hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center. Leuk Res. 2022;119:106885. doi:10.1016/j.leukres.2022.106885
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783–1796. doi:10.1056/NEJMoa1306494
   PubMed Web of Science ®Google Scholar
• Martinelli G, Papayannidis C, Piciocchi A, et al. INCB84344-201: ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia. Blood Advances. 2022;6:1742–1753. doi:10.1182/bloodadvances.2021004821
   PubMed Web of Science ®Google Scholar
• Short NJ, Konopleva M, Kadia T, et al. An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol. 2021;96:E229–E232.
   PubMed Web of Science ®Google Scholar
• Sasaki K, Kantarjian HM, Short NJ, et al. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer. 2021;127:2648–2656. doi:10.1002/cncr.33529
   PubMed Web of Science ®Google Scholar
• Biondi A, Cario G, De Lorenzo P, et al. Long-term follow up of pediatric Philadelphia positive acute lymphoblastic leukemia treated with the EsPhALL2004 study: high white blood cell count at diagnosis is the strongest prognostic factor. Haematologica. 2019;104:––e16. doi:10.3324/haematol.2018.196105
   Web of Science ®Google Scholar
• Ahmed U, Ahmed D, Awan MN, et al. Outcomes of Philadelphia positive acute lymphoblastic leukemia in adolescent and young adults. Cureus. 2022;14:e32467.
   PubMed Web of Science ®Google Scholar
• Braun TP, Eide CA, Druker BJ. Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell. 2020;37:530–542. doi:10.1016/j.ccell.2020.03.006
   PubMed Web of Science ®Google Scholar
• Kodama Y, Manabe A, Kawasaki H, et al. Salvage therapy for children with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Pediatr Blood Cancer. 2017;64(8):e26423. doi:10.1002/pbc.26423
   Web of Science ®Google Scholar
• Gambacorti-Passerini C, Kantarjian HM, Kim DW, et al. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol. 2015;90:755–768. doi:10.1002/ajh.24034
   PubMed Web of Science ®Google Scholar
• Borthakur G, Dombret H, Schafhausen P, et al. A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy. Haematologica. 2015;100:898–904. doi:10.3324/haematol.2014.115279
   PubMed Web of Science ®Google Scholar
• Olivieri A, Manzione L. Dasatinib: a new step in molecular target therapy. Ann Oncol. 2007;18(Suppl 6):42–46.
   Google Scholar
• Malani D, Yadav B, Kumar A, et al. KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia. Leukemia. 2020;34:2780–2784. doi:10.1038/s41375-020-0978-7
   PubMed Web of Science ®Google Scholar
• Gong X, Li L, Wei H, et al. A higher dose of dasatinib May increase the possibility of crossing the blood-brain barrier in the treatment of patients With Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther. 2021;43:1265–1271. doi:10.1016/j.clinthera.2021.05.009
   PubMed Web of Science ®Google Scholar
• Killock D. Dasatinib versus imatinib in paediatric ALL. Nat Rev Clin Oncol. 2020;17:197.
   PubMed Web of Science ®Google Scholar
• Advani AS, Moseley A, O'Dwyer KM, et al. Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia. Blood Advances. 2023;7:1279–1285. doi:10.1182/bloodadvances.2022008216
   PubMed Web of Science ®Google Scholar
• Blay JY, von Mehren M. Nilotinib: a novel, selective tyrosine kinase inhibitor. Semin Oncol. 2011;38(Suppl 1 ):9. doi:10.1053/j.seminoncol.2010.11.010
   Google Scholar
• Tian X, Zhang H, Heimbach T, et al. Clinical pharmacokinetic and pharmacodynamic overview of nilotinib, a selective tyrosine kinase inhibitor. J Clin Pharmacol. 2018;58:1540. doi:10.1002/jcph.1111
   Web of Science ®Google Scholar
• Soverini S, De Benedittis C, Papayannidis C, et al. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer. 2014;120:1002–1009. doi:10.1002/cncr.28522
   PubMed Web of Science ®Google Scholar
• Januzzi JL, Garasic JM, Kasner SE, et al. Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. J Hematol Oncol. 2022;15:1. doi:10.1186/s13045-021-01221-z
   PubMed Web of Science ®Google Scholar
• Pulte ED, Chen H, Price LSL, et al. Fda approval summary: revised indication and dosing regimen for ponatinib based on the results of the OPTIC trial. Oncologist. 2022;27:149–157. doi:10.1093/oncolo/oyab040
   PubMed Web of Science ®Google Scholar
• Marchesi F, Salvatorelli E, Renzi D, et al. Efficacy and safety of low dose ponatinib in a case of Ph-positive acute lymphoblastic leukaemia. Br J Haematol. 2019;187:e15–e17.
   PubMed Web of Science ®Google Scholar
• He JB, Zhang X, Guo ZW, et al. Ponatinib therapy in recurrent Philadelphia chromosome-positive central nervous system leukemia with T315I mutation after allo-HSCT. Int J Cancer. 2020;147:1071–1077. doi:10.1002/ijc.32817
   PubMed Web of Science ®Google Scholar
• Leotta S, Markovic U, Pirosa MC, et al. The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study. Ann Hematol. 2021;100:1743–1753. doi:10.1007/s00277-021-04504-0
   PubMed Web of Science ®Google Scholar
• Chen H, Xu LP, Zhang XH, et al. Safety and outcomes of maintenance therapy with third-generation tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in Philadelphia chromosome positive acute lymphoblastic leukemia patients with T315I mutation. Leuk Res. 2022;121:106930. doi:10.1016/j.leukres.2022.106930
   PubMed Web of Science ®Google Scholar
• Brissot E, Labopin M, Beckers MM, et al. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica. 2015;100:392–399. doi:10.3324/haematol.2014.116954
   PubMed Web of Science ®Google Scholar
• Saleh K, Fernandez A, Pasquier F. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. Cancers (Basel). 2022;14(7):1805. doi: 10.3390/cancers14071805
   PubMed Web of Science ®Google Scholar
• Akahoshi Y, Nishiwaki S, Mizuta S, et al. Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer Sci. 2019;110:3255–3266. doi:10.1111/cas.14167
   PubMed Web of Science ®Google Scholar
• Zhang FH, Ling YW, Zhai X, et al. The effect of imatinib therapy on the outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology. 2013;18:151–157. doi:10.1179/1607845412Y.0000000052
   PubMed Web of Science ®Google Scholar
• Caocci G, Vacca A, Ledda A, et al. Prophylactic and preemptive therapy with dasatinib after hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2012;18:652–654. doi:10.1016/j.bbmt.2011.12.587
   PubMed Web of Science ®Google Scholar
• Webster JA, Luznik L, Tsai HL, et al. Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide. Blood Adv. 2020;4:5078–5088. doi:10.1182/bloodadvances.2020002945
   PubMed Web of Science ®Google Scholar
• Tran TH, Langlois S, Meloche C, et al. Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL consortium protocol 16-001. Blood Adv. 2022;6:1329–1341. doi:10.1182/bloodadvances.2021005634
   PubMed Web of Science ®Google Scholar
• Roberts KG, Morin RD, Zhang J, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell. 2012;22:153–166. doi:10.1016/j.ccr.2012.06.005
   PubMed Web of Science ®Google Scholar
• Sasaki Y, Kantarjian HM, Short NJ, et al. Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD plus dasatinib or ponatinib. Leukemia. 2022;36:1253–1260. doi:10.1038/s41375-021-01496-8
   PubMed Web of Science ®Google Scholar
• Wang J, Jiang Q, Xu LP, et al. Allogeneic stem cell transplantation versus tyrosine kinase inhibitors combined with chemotherapy in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2018;24:741–750. doi:10.1016/j.bbmt.2017.12.777
   PubMed Web of Science ®Google Scholar
• Martinelli G, Iacobucci I, Storlazzi CT, et al. IKZF1 (ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol. 2009;27:––5207. doi:10.1200/jco.2009.27.15_suppl.11005
   Web of Science ®Google Scholar
• Kim M, Park J, Kim DW, et al. Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL. Bone Marrow Transplant. 2015;50:354–362. doi:10.1038/bmt.2014.281
   PubMed Web of Science ®Google Scholar
• Foa R, Bassan R, Vitale A, et al. Dasatinib-Blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med. 2020;383:1613–1623. doi:10.1056/NEJMoa2016272
   PubMed Web of Science ®Google Scholar
• Xie M, Lu Y, Ouyang G, et al. Dasatinib plus prednisone as induction and consolidation for adults with Ph-positive acute lymphoblastic leukaemia: A single-arm, multicentre, phase 2 trial. Br J Haematol. 2023;202:1119–1126. doi:10.1111/bjh.18975
   PubMed Web of Science ®Google Scholar
• Xu N, Li YL, Zhou X, et al. Cdkn2 gene deletion as poor prognosis predictor involved in the progression of adult B-lineage acute lymphoblastic leukemia patients. J Cancer. 2015;6:1114–1120. doi:10.7150/jca.11959
   PubMed Web of Science ®Google Scholar
• Pfeifer H, Raum K, Markovic S, et al. Genomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation. Blood. 2018;131:1464–1475. doi:10.1182/blood-2017-07-796862
   PubMed Web of Science ®Google Scholar
• Fedullo AL, Messina M, Elia L, et al. Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica. 2019;104:312–318. doi:10.3324/haematol.2018.196055
   PubMed Web of Science ®Google Scholar
• Ghobadi A, Slade M, Kantarjian H, et al. The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis. Blood. 2022;140:––2112. doi:10.1182/blood-2022-155582
   Google Scholar
• Lou Y, Ma Y, Li C, et al. Efficacy and prognostic factors of imatinib plus CALLG2008 protocol in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Front Med. 2017;11:229–238. doi:10.1007/s11684-017-0506-y
   PubMed Web of Science ®Google Scholar
• Saini N, Marin D, Ledesma C, et al. Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL. Blood. 2020;136:1786–1789. doi:10.1182/blood.2019004685
   PubMedGoogle Scholar
• Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol. 2009;27:5175–5181. doi:10.1200/JCO.2008.21.2514
   PubMed Web of Science ®Google Scholar
• Chang J, Douer D, Aldoss I, et al. Combination chemotherapy plus dasatinib leads to comparable overall survival and relapse-free survival rates as allogeneic hematopoietic stem cell transplantation in Philadelphia positive acute lymphoblastic leukemia. Cancer Med. 2019;8:2832–2839. doi:10.1002/cam4.2153
   PubMed Web of Science ®Google Scholar
• Zeng Q, Xiang B, Liu Z. Comparison of allogeneic hematopoietic stem cell transplantation and TKI combined with chemotherapy for adult Philadelphia chromosome positive acute lymphoblastic leukemia: a systematic review and meta-analysis. Cancer Med. 2021;10:––8753. doi:10.1002/cam4.3834
   Web of Science ®Google Scholar
• Short NJ, Kantarjian HM, Ravandi F, et al. Efficacy and safety outcomes in the phase 3 INO-vate trial By baseline CD22 positivity assessed By local laboratories. Blood. 2019;134:1344––11344. doi:10.1182/blood-2019-122097
   Web of Science ®Google Scholar
• Jabbour E, Short NJ, Jain N, et al. The evolution of acute lymphoblastic leukemia research and therapy at MD anderson over four decades. J Hematol Oncol. 2023;16:22. doi:10.1186/s13045-023-01476-8
   PubMed Web of Science ®Google Scholar
• Couturier MA, Thomas X, Raffoux E, et al. Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. Leuk Lymphoma. 2021;62:620–629. doi:10.1080/10428194.2020.1844198
   PubMed Web of Science ®Google Scholar
• Tian Y, Ai H, Wei JX, et al. Efficacy analysis of venetoclax combined with TKI and dexamethasone-containing low-dose chemotherapy for relapsed/refractory Ph(+)acute B-lymphoblastic leukemia. Zhonghua yi xue za zhi. 2022;102:745–748.
   PubMedGoogle Scholar
• Wang H, Yang C, Shi T, et al. Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia. Blood Cancer J. 2022;12:20. doi:10.1038/s41408-022-00621-9
   PubMed Web of Science ®Google Scholar
• Jabbour EJ, Short NJ, Jain N, et al. Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10(-4) and higher. Am J Hematol. 2022;97:1135–1141. doi:10.1002/ajh.26634
   PubMed Web of Science ®Google Scholar
• Martinelli G, Boissel N, Chevallier P, et al. Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: final analysis of ALCANTARA study. Eur J Cancer. 2021;146:107–114. doi:10.1016/j.ejca.2020.12.022
   PubMed Web of Science ®Google Scholar
• Boissel N, Chiaretti S, Papayannidis C, et al. Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study. Blood Cancer J. 2023;13(2).
   PubMedGoogle Scholar
• Jabbour E, Short NJ, Jain N, et al. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2023;10:––e34. doi:10.1016/S2352-3026(23)00064-9
   Web of Science ®Google Scholar
• Yang F, Yang X, Bao X, et al. Anti-CD19 chimeric antigen receptor T-cells induce durable remission in relapsed Philadelphia chromosome-positive ALL with T315I mutation. Leuk Lymphoma. 2020;61:429–436. doi:10.1080/10428194.2019.1663417
   PubMed Web of Science ®Google Scholar
• Leahy AB, Devine KJ, Li Y, et al. Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy. Blood. 2022;139:2173–2185. doi:10.1182/blood.2021012727
   PubMed Web of Science ®Google Scholar
• Yang J, He J, Zhang X, et al. Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study. Blood Cancer J. 2022;12:104. doi:10.1038/s41408-022-00694-6
   PubMed Web of Science ®Google Scholar
• Zhang X, Lu XA, Yang J, et al. Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. Blood Adv. 2020;4:2325–2338. doi:10.1182/bloodadvances.2020001466
   PubMed Web of Science ®Google Scholar
• Sasaki K, Kantarjian H, Wierda W, et al. Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol. 2020;95:734–739. doi:10.1002/ajh.25784
   PubMed Web of Science ®Google Scholar
• Marks DI, Kirkwood AA, Rowntree CJ, et al. Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial. Lancet Haematol. 2022;9:e262–e275.
   PubMed Web of Science ®Google Scholar
• Jain N, Maiti A, Ravandi F, et al. Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. Am J Hematol. 2021;96:––1007. doi:10.1002/ajh.26061
   Web of Science ®Google Scholar
• Senapati J, Short N, Alvarado Y, et al. A phase II study of inotuzumab ozogamicin for the treatment of measurable residual disease-positive B-cell acute lymphoblastic leukemia. Blood. 2022;140:3253–3255. doi:10.1182/blood-2022-170667
   Web of Science ®Google Scholar
• Stock W, Martinelli G, Stelljes M, et al. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia. Cancer. 2021;127:905–913. doi:10.1002/cncr.33321
   PubMed Web of Science ®Google Scholar
• Leonard JT, Rowley JSJ, Eide CA, Traer E, Hayes-Lattin B, Loriaux M, Spurgeon SE, et al. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia. Sci Transl Med 2016;8:354ra114.
   Web of Science ®Google Scholar
• [De] Dominici M, Porazzi P, Soliera AR, et al. Targeting CDK6 and BCL2 exploits the “MYB addiction” of Ph(+) acute lymphoblastic leukemia. Cancer Res. 2018;78:1097–1109. doi:10.1158/0008-5472.CAN-17-2644
   PubMed Web of Science ®Google Scholar
• Massimino M, Vigneri P, Stella S, et al. Combined inhibition of Bcl2 and Bcr-Abl1 exercises anti-leukemia activity but does Not eradicate the primitive leukemic cells. J Clin Med. 2021;10:5606. doi:10.3390/jcm10235606
   PubMed Web of Science ®Google Scholar
• Hesham HM, Lasheen DS, Abouzid KAM. Chimeric HDAC inhibitors: comprehensive review on the HDAC-based strategies developed to combat cancer. Med Res Rev. 2018;38:2058–2109. doi:10.1002/med.21505
   PubMed Web of Science ®Google Scholar
• Marks PA. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs. 2010;19:1049–1066. doi:10.1517/13543784.2010.510514
   PubMed Web of Science ®Google Scholar
• Yang L, Qiu Q, Tang M, et al. Purinostat mesylate Is a uniquely potent and selective inhibitor of HDACs for the treatment of BCR-ABL-induced B-cell acute lymphoblastic leukemia. Clin Cancer Res. 2019;25:7527–7539. doi:10.1158/1078-0432.CCR-19-0516
   PubMed Web of Science ®Google Scholar
• Tharkar-Promod S, Johnson DP, Bennett SE, et al. HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia. Leukemia. 2018;32:49–60. doi:10.1038/leu.2017.174
   PubMed Web of Science ®Google Scholar
• Okabe S, Tauchi T, Ohyashiki K. Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells. Ann Hematol. 2010;89:1081–1087. doi:10.1007/s00277-010-0998-x
   PubMed Web of Science ®Google Scholar
• Losson H, Gajulapalli SR, Lernoux M, et al. The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia. Pharmacol Res. 2020;160:105058. doi:10.1016/j.phrs.2020.105058
   PubMed Web of Science ®Google Scholar
• Dasmahapatra G, Patel H, Nguyen T, et al. PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013;19:6766––66776. doi:10.1158/1078-0432.CCR-13-0128
   PubMed Web of Science ®Google Scholar
• Del Nagro CJ, Otero DC, Anzelon AN, et al. CD19 function in central and peripheral B-cell development. Immunol Res 2005;31:119–132. doi:10.1385/IR:31:2:119
   PubMed Web of Science ®Google Scholar
• Tabernero MD, Bortoluci AM, Alaejos I, et al. Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expression. Leukemia. 2001;15:406–414. doi:10.1038/sj.leu.2402060
   PubMed Web of Science ®Google Scholar
• Rosenthal J, Naqvi AS, Luo M, et al. Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia. Am J Hematol. 2018;93:E352–E355.
   PubMed Web of Science ®Google Scholar
• Wu J, Fu J, Zhang M, et al. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. J Hematol Oncol. 2015;8:104. doi:10.1186/s13045-015-0195-4
   PubMed Web of Science ®Google Scholar
• Zhao Y, Aldoss I, Qu C, et al. Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. Blood. 2021;137:471–484. doi:10.1182/blood.2020006287
   PubMed Web of Science ®Google Scholar
• Rambaldi A, Ribera JM, Kantarjian HM, et al. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome–positive B-precursor acute lymphoblastic leukemia. Cancer. 2020;126:304–310. doi:10.1002/cncr.32558
   PubMed Web of Science ®Google Scholar
• Puzzolo MC, Radice G, Peragine N, et al. Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab. Blood. 2021;138:2290–2293.
   PubMed Web of Science ®Google Scholar
• Wang Z, Wu Z, Liu Y, et al. New development in CAR-T cell therapy. J Hematol Oncol. 2017;10:53. doi:10.1186/s13045-017-0423-1
   PubMed Web of Science ®Google Scholar
• He J, Xu N, Zhou H, et al. Case report: chimeric antigen receptor T cells induced late severe cytokine release syndrome. Front Oncol. 2022;12:893928. doi:10.3389/fonc.2022.893928
   PubMed Web of Science ®Google Scholar
• Teachey DT, Lacey SF, Shaw PA, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6:664–679. doi:10.1158/2159-8290.CD-16-0040
   PubMed Web of Science ®Google Scholar
• Hernani R, Benzaquen A, Solano C. Toxicities following CAR-T therapy for hematological malignancies. Cancer Treat Rev. 2022;111:102479. doi:10.1016/j.ctrv.2022.102479
   PubMed Web of Science ®Google Scholar
• Zhu YM, Wu Z, Tan YP, et al. Anti-CD19 chimeric antigen receptor T-cell therapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Medicine (Baltimore). 2016;95:e5676. doi:10.1097/MD.0000000000005676
   PubMed Web of Science ®Google Scholar
• Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16:372–385.
   PubMed Web of Science ®Google Scholar
• Pavlasova G, Mraz M. The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy. Haematologica. 2020;105:1494–1506. doi:10.3324/haematol.2019.243543
   PubMed Web of Science ®Google Scholar
• Jaso J, Thomas DA, Cunningham K, et al. Prognostic significance of immunophenotypic and karyotypic features of Philadelphia positive B-lymphoblastic leukemia in the era of tyrosine kinase inhibitors. Cancer. 2011;117:4009–4017. doi:10.1002/cncr.25978
   PubMed Web of Science ®Google Scholar
• Pierpont TM, Limper CB, Richards KL. Past, present, and future of rituximab—The world’s first oncology monoclonal antibody therapy. Front Oncol. 2018;8:163. doi:10.3389/fonc.2018.00163
   PubMed Web of Science ®Google Scholar
• Cassaday RD, Stevenson PA, Wood BL, et al. Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD. Am J Hematol 2018;93:546–552. doi:10.1002/ajh.25030
   PubMed Web of Science ®Google Scholar
• Clark EA, Giltiay NV. Cd22: A regulator of innate and adaptive B cell responses and autoimmunity. Front Immunol. 2018;9:2235. doi:10.3389/fimmu.2018.02235
   PubMed Web of Science ®Google Scholar
• Corrente F, Bellesi S, Metafuni E, et al. Role of flow-cytometric immunophenotyping in prediction of BCR/ABL1 gene rearrangement in adult B-cell acute lymphoblastic leukemia. Cytometry B Clin Cytom. 2018;94:468–476. doi:10.1002/cyto.b.21605
   PubMed Web of Science ®Google Scholar
• Lamb YN. Inotuzumab ozogamicin: first global approval. Drugs. 2017;77:1603–1610. doi:10.1007/s40265-017-0802-5
   PubMed Web of Science ®Google Scholar
• Pirosa MC, Leotta S, Cupri A, et al. Long-Term molecular remission achieved by antibody anti-CD22 and ponatinib in a patient affected by Ph'+ acute lymphoblastic leukemia relapsed after second allogeneic hematopoietic stem cell transplantation: A case report. Chemotherapy. 2018;63:220–224. doi:10.1159/000492941
   PubMed Web of Science ®Google Scholar
• Micheva I, Gerov V, Dimitrova S, et al. Efficacy of inotuzumab ozogamicin plus ponatinib followed by allogeneic stem cell transplantation in a patient with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia. Case Rep Hematol. 2021;2021:1717506.
   PubMed Web of Science ®Google Scholar
• Molica M, Mazzone C, Cordone I, et al. Durable molecular remission in an elderly patient affected by relapsed Ph'+ acute lymphoblastic leukemia with T315I and concomitant p190 and p210 expression achieved by inotuzumab and ponatinib. Chemotherapy. 2021;66:78–81. doi:10.1159/000516593
   PubMed Web of Science ®Google Scholar
• Krupka C, Kufer P, Kischel R, et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood. 2014;123:356–365. doi:10.1182/blood-2013-08-523548
   PubMed Web of Science ®Google Scholar
• Cimino G, Pane F, Elia L, et al. The role of BCR/ABL isoforms in the presentation and outcome of patients with Philadelphia-positive acute lymphoblastic leukemia: a seven-year update of the GIMEMA 0496 trial. Haematologica. 2006;91:377–380.
   PubMed Web of Science ®Google Scholar
• Ohki K, Takahashi H, Fukushima T, et al. Impact of immunophenotypic characteristics on genetic subgrouping in childhood acute lymphoblastic leukemia: Tokyo children's cancer study group (TCCSG) study L04-16. Genes Chromosomes Cancer. 2020;59:551–561. doi:10.1002/gcc.22858
   PubMed Web of Science ®Google Scholar
• Golay J, Di Gaetano N, Amico D, et al. Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo. Br J Haematol 2005;128:310–317. doi:10.1111/j.1365-2141.2004.05322.x
   PubMed Web of Science ®Google Scholar
• Chevallier P, Mahe B, Garand R, et al. Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression. Int J Hematol. 2008;88:209–211. doi:10.1007/s12185-008-0123-2
   PubMed Web of Science ®Google Scholar
• de Vetten MP, Jansen JH, van der Reijden BA, et al. Molecular remission of Philadelphia/bcr-abl-positive acute myeloid leukaemia after treatment with anti-CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA-676). Br J Haematol. 2000;111:277–279.
   PubMed Web of Science ®Google Scholar